Related Experiment Video
Updated: Jun 20, 2026
13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Sunitinib for advanced renal cell cancer
1BC Cancer Agency and University of British Columbia, Vancouver, Canada.
Biologics : Targets & Therapy
|August 27, 2009
Summary
Sunitinib offers improved outcomes for metastatic renal cell cancer compared to interferon-alfa, though overall survival benefits are still under investigation. Further research is needed due to cost and efficacy limitations.
Area of Science:
- Oncology
- Pharmacology
Background:
- Renal cell cancer (RCC) is largely unresponsive to conventional drug therapies.
- Targeted therapies, such as sunitinib, have emerged as a focus in RCC treatment.
- Sunitinib targets multiple tyrosine kinase receptors involved in angiogenesis.
Purpose of the Study:
- To review the rationale, development, validation, and clinical application of sunitinib for renal cell cancer.
- To evaluate sunitinib's efficacy and safety in patients with metastatic clear-cell RCC.
Main Methods:
- Review of existing literature on sunitinib's development and clinical trials.
- Comparison of sunitinib with interferon-alfa in first-line treatment for metastatic RCC.
- Analysis of surrogate and patient-reported outcomes, overall survival, and toxicity.
Main Results:
- Sunitinib demonstrated superior surrogate and patient-reported outcomes compared to interferon-alfa in clear-cell RCC with good/moderate prognostic factors.
- Overall survival improvement over interferon-alfa was not yet demonstrated, partly due to patient crossover.
- Significant but manageable toxicity was observed with sunitinib therapy.
Conclusions:
- Sunitinib represents a significant advancement in treating advanced renal cell cancer.
- High cost and limitations in efficacy necessitate continued research for improved therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...